Home  |  Contact

Cellosaurus LB831-BLC (CVCL_1370)

[Text version]

Cell line name LB831-BLC
Synonyms LB831BLC; LB831
Accession CVCL_1370
Resource Identification Initiative To cite this cell line use: LB831-BLC (RRID:CVCL_1370)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Homozygous for TP53 p.Ser241Tyr (c.722C>A) (ClinVar=VCV000376663) (CCLE; Cosmic-CLP).
HLA typing Source: PubMed=9637538
Class I
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0.49
East Asian, North0
East Asian, South0.01
South Asian2.75
European, North63.52
European, South33.23
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_E913 ! LB831-EBV
Sex of cell Male
Age at sampling 65Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP


Run an STR similarity search on this cell line

Gueguen M., Patard J.-J., Gaugler B., Brasseur F., Renauld J.-C., Van Cangh P.J., Boon T., van den Eynde B.J.
An antigen recognized by autologous CTLs on a human bladder carcinoma.
J. Immunol. 160:6188-6194(1998)

Gala J.-L., Loric S., Guiot Y., Denmeade S.R., Gady A., Brasseur F., Heusterspreute M., Eschwege P., De Nayer P., Van Cangh P.J., Tombal B.
Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value?
Clin. Cancer Res. 6:4049-4054(2000)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=29732388; DOI=10.3233/BLC-180167
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

Cell line databases/resources CCLE; LB831BLC_URINARY_TRACT
Cell_Model_Passport; SIDM00181
Cosmic-CLP; 753584
DepMap; ACH-002266
TOKU-E; 3997
Chemistry resources ChEMBL-Cells; CHEMBL3308853
ChEMBL-Targets; CHEMBL2366222
GDSC; 753584
PharmacoDB; LB831BLC_826_2019
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM1670039
Other Wikidata; Q54902093
Polymorphism and mutation databases Cosmic; 753584
IARC_TP53; 21467
Entry history
Entry creation04-Apr-2012
Last entry update12-Jan-2021
Version number27